trending Market Intelligence /marketintelligence/en/news-insights/trending/fNViiYlk4fHNRRf5sHvqOw2 content esgSubNav
In This List

Grifols gets US FDA green light for blood testing system

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Grifols gets US FDA green light for blood testing system

Grifols SA obtained approval from the U.S. Food and Drug Administration for Erytra Eflexis, its benchtop analyzer for blood testing.

The system uses Grifols' DG Gel technology to ensure that the blood of a transfusion recipient and the donor are compatible.

Erytra Eflexis, which received the European Commission's CE Mark in June 2017, can be used as a stand-alone system or in combination with other Grifols blood typing portfolio solutions, the Spanish healthcare company said.